Clinical trial transparency: Many gains but access to evidence for new medicines remains imperfect

British Medical Bulletin

Volumn 116, Issue 1, 2015, Pages 43-53

  Mintzes, Barbara ^a   Lexchin, Joel ^b,c,d   Quintano, Ancella Santos ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b YORK UNIVERSITY   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Vancouver BC   (Netherlands)

Author keywords

clinical trial data transparency; European Medicines Agency; Food and Drug Administration; pharmaceutical regulation

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; CLINICAL TRIAL (TOPIC); CONFIDENTIALITY; DRUG INDUSTRY; EUROPE; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION; INTERPERSONAL COMMUNICATION; MEDICAL RESEARCH; MEDICINE; PRIORITY JOURNAL; REGISTRATION; DRUG THERAPY; EVIDENCE BASED MEDICINE; INFORMATION DISSEMINATION; PROCEDURES; PUBLISHING; STANDARDS; TRENDS;

ACCESS TO INFORMATION; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CONFIDENTIALITY; DRUG INDUSTRY; DRUG THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; INFORMATION DISSEMINATION; PUBLICATION BIAS;

EID: 84950274688     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldv042     Document Type: Article

References (67)

1. Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010;14:1-193.
2. Budnitz D, Lovegrove M, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-12.
3. Commission of the European Communities. Commission Staff Working Document: Impact Assessment Volume 2014. Brussels, 2008.
4. Graham D, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
5. Mamdani M, Juurlink D, Kopp A, et al. Gastrointestinal bleeding after the introduction of COX-2 inhibitors: ecological study. BMJ 2004;328:1415-6.
6. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.
7. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008;5:e217.
8. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
9. Garland EJ. Facing the evidence: antidepressant treatment in children and adolescents. CMAJ 2004;170:489-91.
10. Kondro W, Sibbald B. Drug company experts advised staff to withhold data about SSRI use in children. CMAJ 2004;170:783.
11. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762-72.
12. Van Noorden R. Report disputes benefit of stockpiling Tamiflu. Nature 2014. doi:10.1038/nature.2014.15022. Available at: http://www.nature.com/news/report-disputesbenefit-of-stockpiling-tamiflu-1.15022 (1 October 2015, date last accessed).
13. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012;1:CD008965.
14. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667-72.
15. Anderson ML, Chiswell K, Peterson ED, et al. Compliance with results reporting at Clinical Trials.gov. N Engl J Med 2015;372:1031-9.
16. Wieseler B, Wolfram N, McGauran N, et al. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoSMed 2013;10:e1001526.
17. Wieseler B, Kerekes MF, Vervoelgyi V, et al. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ 2011;344:d8141.
18. Jones CW, Handler L, Crowell KE, et al. Nonpublication of large randomized clinical trials: cross sectional analysis. BMJ 2013;347:f6104.
19. Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ 2012;344:d7202.
20. Schroll JB, Bero L. Regulatory agencies hold the key to improving Cochrane reviews of drugs. Cochrane Database Syst Rev 2015;4:ED000098.
21. Kohler M, Haag S, Biester K, et al. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports. BMJ 2015;350: h796.
22. Habibi R, Lexchin J. Quality and quantity of information in summary basis of decision documents issued by health Canada. PLoS One 2014;9:e92038.
23. Lurie P, Chahal H, Sigelman D, et al. Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross-sectional study. BMJ 2015;350:h2758.
24. Hakala A, Kimmelman J, Carlisle B, et al. Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials. BMJ 2015;350: h1116.
25. Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737.
26. Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev 2014; DOI: 10.1002/14651858.CD008965.pub4.
27. Pharmaceutical Research and Manufacturers of America, European Federation of Pharmaceutical Industries and Associations. Principles for responsible clinical trial data sharing: our commitment to patients and researchers. 2013. Available at: http://www.phrma.org/sites/default/files/pdf/PhRMAPrinciplesForResponsibleClinicalTrialDataSharing.pdf (1 October 2015, date last accessed).
28. European Ombudsman. Draft recommendation of the European Ombudsman in his inquiry into complaint 2560/2007/BEH against the European Medicines Agency, 2010.
29. Lemmens T. EMA's proposed data release policy: promoting transparency or expanding pharma control over data? PLoS Blogs, 2014. Available at: http://blogs.plos.org/speakingofmedicine/2014/05/30/emas-new-data-releasepolicy-promoting-transparency-expanding-pharma-controldata/ (1 October 2015, date last accessed).
30. European Federation of Pharmaceutical Industries and Associations. EFPIA welcomes the Commission's proposal on the protection of undisclosed know-how and business information ("Trade Secrets"), 2013. Available at: http://www.efpia.eu/mediaroom/129/44/EFPIA-welcomes-the-Commission-39-s-Proposal-on-the-protection-of-undisclosedknow-how-and-business-information-quot-Trade-Secrets-quot (1 October 2015, date last accessed).
31. Taylor J. Re: request for comments concerning the proposed transatlantic trade and investment partnership, 78 Fed. Reg. 19566 (Apr. 1, 2013). Washington, DC: PhRMA, 2013.
32. Hirsch L. Randomized clinical trials: why gets published, and when? CMAJ 2004;170:481-3.
33. European Medicines Agency. Draft proposal for an addendum, on transparency, to the "functional specifications for the EU portal and EU database to be audited-EMA/42176/2014, 2015.
34. Silverman E. Sparring begins over a European policy for disclosing clinical trial data. WSJ.com: Wall Street Journal, 2015. Available at: http://blogs.wsj.com/pharmalot/2015/02/26/sparring-begins-over-a-european-policy-for-disclosingclinical-trial-data/
35. Hughes S, Cohen D, Jaggi R. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. BMJ Open 2014;4:e005535.
36. Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med 2013; 369:475-8.
37. Krumholz H. Give the data to the people. New York Times, 2014. Available at: http://www.nytimes.com/2014/02/03/opinion/give-the-data-to-the-people.html?-r=0 (1 October 2015, date last accessed).
38. Rosenblatt M. Unlocking the full potential of clinical trial data-sharing. Viewpoints from the chief medical officer: Merck, 2015.
39. Copley C. Switzerland's Roche pledges to open up access to drug data: Reuters.com, 2013. Available at: http://www.reuters.com/article/2013/02/27/us-roche-data-accessidUSBRE91P0PK20130227 (1 October 2015, date last accessed).
40. Strom B, Buyse M, Hughes J, et al. Data sharing, year 1-access to data from industry-sponsored clinical trials. N Engl J Med 2014;371:2052-4.
41. ClinicalStudy Data Request.com, About this site. 2015. Available at: https://clinicalstudydatarequest.com (1 October 2015, date last accessed).
42. Metrics: Clinical Study Data Request.com, 2015. Available at: https://clinicalstudydatarequest.com/Metrics.aspx (1 October 2015, date last accessed).
43. Kmietowicz Z. Roche says it will not relinquish control over access to clinical trial data. BMJ 2013;346:f1374.
44. Case T-44/13 R, Abbvie v. EMA volume OJ 2013 C79/53, 2013.
45. Case T-29/13 R Abbvie v. EMA volume OJ 2013 C79/46, 2013.
46. Case T-73/13, Intermune UK and others v. EMA volume OJ 2013 C114/60, 2013.
47. Bonini S, Eichler H-G, Wathion N, et al. Transparency and the European Medicines Agency-sharing of clinical trial data. N Engl J Med 2014;371:2452-5.
48. Eichler H-G, Pétavy F, Pignatti F, et al. Access to patientlevel trial data-a boon to drug developers. N Engl J Med 2013;369:1577-9.
49. Barron H, Rosenblatt M. Access to patient-level trial data. N Engl J Med 2014;370:485-6.
50. Boseley S. Drug trials firm to challenge plans for greater transparency over results: The Guardian, 2015. Available at: http://www.theguardian.com/business/2015/may/18/drug-trials-firm-to-challenge-plans-for-greater-transparencyover-results (1 October 2015, date last accessed).
51. Zetterqvist A, Merlo J, Mulinari S. Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry selfregulation. PLoS Med 2015;12:e1001785.
52. Doshi P, Goodman SN, Ioannidis JP. Raw data from clinical trials: within reach? Trends Pharmacol Sci 2013;34: 645-7.
53. European Federation of Pharmaceutical Industries and Associations. EFPIA response to EMA consultation on the publication and access to clinical-trial data, 2013. Available at: http://www.efpia.eu/mediaroom/118/44/EFPIA-Response-to-EMA-Consultation-on-the-Publicationand-Access-to-Clinical-Trial-Data (1 October 2015, date last accessed).
54. Mello M, Francer J, Wilenzick M, et al. Preparing for responsible sharing of clinical trial data. N Engl J Med 2013;369:1651-7.
55. Lemmens T. Pharmaceutical knowledge governance: a human rights perspective. J Law Med Ethics 2013;41: 163-84.
56. Clinical Trials.gov: US National Institutes of Health, 2015.
57. AllTrials. London: Sense About Science, 2014.
58. All trials registered | All Trials Reported. London: All-Trials, 2015.
59. Goldacre B. How to get all trials reported: audit, better data, and individual accountability. PLoS Med 2015;12: e1001821.
60. Regulation (EU) No. 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, 2014.
61. Health Action International. Protecting citizens' health: transparency of clinical trial data on medicines in the EU, 2013. Available at: http://haiweb.org/wp-content/uploads/2015/09/Transparency-of-Clinical-Trial-Data-on-Medicinesin-the-EU.pdf (1 October 2015, date last accessed).
62. Doshi P. EMA policy on transparency is "strikingly" similar to deal struck with drug company, say experts. BMJ 2014;348:g3852.
63. European Ombudsman. Ombudsman concerned about change of policy at Medicines Agency as regards clinical trial data transparency, 2014. Available at: http://www.ombudsman.europa.eu/en/press/release.faces/en/54348/html.bookmark (1 October 2015, date last accessed).
64. European Medicines Agency. European Medicines Agency policy on publication of clinical data for medicinal products for human use, EMA/240810/2013. 2014. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Other/2014/10/WC500174796.pdf (1 October 2015, date last accessed).
65. European Medicines Agency. Current status of European Medicines Agency policy on publication of clinical data-stakeholder webinar. London, 2015. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/events/2015/06/event-detail-001163. jsp&mid=WC0b01ac058004d5c3 (1 October 2015, date last accessed).
66. World Health Organization. WHO statement on public disclosure of clinical trial results, 2015. Available at: http://www.who.int/ictrp/results/reporting/en/ (1 October 2015, date last accessed).
67. Department of Health and Human Services. Clinical trials registration and results submission; proposed rule. Fed Regist 2014;79:69566-680.